A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Advanced Breast Cancer|Metastatic Castration Resistant Prostate Cancer|Metastatic Renal Cell Cancer|Non-Small Cell Lung Cancer|Thyroid Cancer|Advanced/Metastatic Non-Small Cell Lung Cancer|Advanced Gastric Cancer|Gastrointestinal Stromal Tumor|Hepatocellular Carcinoma|Pancreatic Islet Cell Carcinoma|Pancreatic Neuroendocrine Tumor
Interventions: DRUG: sunitinib
Sponsor: Pfizer